8GF2 image
Entry Detail
PDB ID:
8GF2
Title:
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies eCR3022.20 and CC12.3
Biological Source:
PDB Version:
Deposition Date:
2023-03-07
Release Date:
2023-08-23
Method Details:
Experimental Method:
Resolution:
2.85 Å
R-Value Free:
0.25
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Spike protein S1
Chain IDs:A, F (auth: B)
Chain Length:231
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Description:CC12.3 Fab heavy chain
Chain IDs:B (auth: C), G (auth: E)
Chain Length:220
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:CC12.3 Fab light chain
Chain IDs:C (auth: D), H (auth: F)
Chain Length:215
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:eCR3022.20 Fab heavy chain
Chain IDs:D (auth: H), I (auth: X)
Chain Length:222
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:eCR3022.20 Fab light chain
Chain IDs:E (auth: L), J (auth: Y)
Chain Length:221
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution.
Sci.Signal. 16 eabk3516 eabk3516 (2023)
PMID: 37582161 DOI: 10.1126/scisignal.abk3516

Abstact

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need for strategies to rapidly develop neutralizing monoclonal antibodies that can function as prophylactic and therapeutic agents and to help guide vaccine design. Here, we demonstrate that engineering approaches can be used to refocus an existing antibody that neutralizes one virus but not a related virus. Through a rapid affinity maturation strategy, we engineered CR3022, a SARS-CoV-1-neutralizing antibody, to bind to the receptor binding domain of SARS-CoV-2 with >1000-fold increased affinity. The engineered CR3022 neutralized SARS-CoV-2 and provided prophylactic protection from viral challenge in a small animal model of SARS-CoV-2 infection. Deep sequencing throughout the engineering process paired with crystallographic analysis of engineered CR3022 elucidated the molecular mechanisms by which the antibody can accommodate sequence differences in the epitopes between SARS-CoV-1 and SARS-CoV-2. This workflow provides a blueprint for the rapid broadening of neutralization of an antibody from one virus to closely related but resistant viruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures